Physician profile
Andrea L Gropman
NPI 1407848005
$36,082.61
in general payments reported to CMS, 2019-2025
15 companies · $7,254 in 2025
The $7,254 reported for 2025 was more than what 88% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,789 · 2020: $2,175 · 2021: $4,125 · 2022: $346 · 2023: $16K · 2024: $340 · 2025: $7,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Honoraria: $9,450 · Food and Beverage: $1,640 · Travel and Lodging: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,648.41 |
| Honoraria | $9,450.00 |
| Food and Beverage | $1,640.43 |
| Travel and Lodging | $909.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $10,752.24 | 2023 | Ravicti |
| Shire North American Group INC | $5,729.10 | 2019 | |
| Immedica Pharma US, INC. | $5,600.00 | 2025 | Pegzilarginase |
| Acadia Pharmaceuticals INC | $5,128.41 | 2023 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $4,350.00 | 2020-2021 | |
| Biomarin Pharmaceutical INC. | $2,562.80 | 2019-2025 | Brineura, Palynziq |
| Tanabe Pharma America, INC. | $920.00 | 2025 | |
| United Imaging Healthcare North America, INC. | $305.00 | 2025 | N/A |
| Eagle Pharmaceuticals, INC. | $225.00 | 2020 | |
| Ucb, INC. | $178.84 | 2024-2025 | Fintepla |
| Ptc Therapeutics, INC. | $161.95 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $144.07 | 2025 | |
| Zevra Therapeutics INC | $19.53 | 2024 | Olpruva |
| Sentynl Therapeutics, INC. | $5.67 | 2024 | Nulibry |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Gropman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.